Franklin Biotechnology Discovery has an experienced team at the helm, but it needs to distinguish itself.
Franklin Biotechnology Discovery R6 FRBRX
- NAV / 1-Day Return 156.03 / −1.29 %
- Total Assets 909.8 Mil
-
Adj. Expense Ratio
- Expense Ratio 0.690%
- Distribution Fee Level Low
- Share Class Type Retirement, Large
- Category Health
- Investment Style Mid Growth
- Min. Initial Investment 1.0 Mil
- Status Open
- TTM Yield 0.00
- Turnover 36%
USD | NAV as of Sep 26, 2024 | 1-Day Return as of Sep 26, 2024, 10:10 PM GMT+0
Morningstar’s Analysis FRBRX
Will FRBRX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 43.2
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Amgen Inc | 8.16 | 77.4 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 7.78 | 73.7 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 6.00 | 56.9 Mil | Healthcare |
Insmed Inc | 3.92 | 37.1 Mil | Healthcare |
Gilead Sciences Inc | 3.37 | 31.9 Mil | Healthcare |
AstraZeneca PLC ADR | 3.11 | 29.5 Mil | Healthcare |
Biogen Inc | 2.79 | 26.5 Mil | Healthcare |
Intra-Cellular Therapies Inc | 2.75 | 26.0 Mil | Healthcare |
Merus NV | 2.69 | 25.5 Mil | Healthcare |
Jazz Pharmaceuticals PLC | 2.65 | 25.1 Mil | Healthcare |